View Archive »
About The Cover
The cover for issue 99 of Oncotarget features Figure 1C, "Schematic representation of atuveciclib mode of action," by Brisard, et al.
|
|
Table of Contents
News
|
| Prospective investigation of drug resistance: an approach to understanding and optimizing the clinical benefit of targeted agents in Ewing sarcoma |
|
https://doi.org/10.18632/oncotarget.26465
|
| 37270-37271 |
|
| Sequence variation in the microRNA region of a cancer virus |
|
https://doi.org/10.18632/oncotarget.26471
|
| 37272-37273 |
Editorial
|
| Unveiling resistance mechanisms to EGFR inhibitors in cholangiocarcinoma |
|
https://doi.org/10.18632/oncotarget.26403
|
| 37274-37275 |
|
| Battling quiescence for tumor eradication: too good to be true |
|
https://doi.org/10.18632/oncotarget.26452
|
| 37276-37277 |
|
| Revisiting entinostat as an immunepotentiating adjuvant |
|
https://doi.org/10.18632/oncotarget.26453
|
| 37278-37279 |
|
| Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors |
|
https://doi.org/10.18632/oncotarget.26460
|
| 37280-37281 |
|
| Exosomal transmission between macrophages and cancer cells: new insights to stromamediated drug resistance |
|
https://doi.org/10.18632/oncotarget.26463
|
| 37282-37283 |
|
| Reversing resistance to antiandrogens with a histone deacetylase inhibitor |
|
https://doi.org/10.18632/oncotarget.26464
|
| 37284-37285 |
|
| Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins |
|
https://doi.org/10.18632/oncotarget.26466
|
| 37286-37288 |
|
| Cellsurface GPNMB and induction of stemness |
|
https://doi.org/10.18632/oncotarget.26472
|
| 37289-37290 |
Research Papers
|
| Phosphorylated Akt1 expression is associated with poor prognosis in cutaneous oral and sinonasal melanomas |
|
https://doi.org/10.18632/oncotarget.26458
|
| 37291-37304 |
|
| Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stemlike cells in triplenegative breast cancer |
|
https://doi.org/10.18632/oncotarget.26468
|
| 37305-37318 |
|
| Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin cotreatment |
|
https://doi.org/10.18632/oncotarget.26470
|
| 37319-37332 |
|
| Fluorescent humanized antiCEA antibody specifically labels metastatic pancreatic cancer in a patientderived orthotopic xenograft PDOX mouse model |
|
https://doi.org/10.18632/oncotarget.26484
|
| 37333-37342 |
Corrections
|
| Correction: Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation |
|
https://doi.org/10.18632/oncotarget.26504
|
| 37343-37343 |
|
| Correction: PreImplantation factor PIF protects cultured embryos against oxidative stress: relevance for recurrent pregnancy loss RPL therapy |
|
https://doi.org/10.18632/oncotarget.26505
|
| 37344-37344 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
